Replies to post #28394 on Cardiff Lexington Corp (CDIX)

[KeepItRealistic]

Another far fetched post ...

Just grab the shares and enjoy the ride up !

$CDIX keep an eye out for an Acela Acquisition 8k

No dilution, notes payed

4 days running, Float remains at 402 mil
SS snapshots on 19th & 20th & 17th

$CDIX SS unchanged again pic.twitter.com/CKy9YjWnmr

— KIR (@KeepRealistic) September 21, 2019

$CDIX SS on the 17th pic.twitter.com/zzOoivcRru

— KIR (@KeepRealistic) September 21, 2019

There is only one logical reason to pay off notes and stop price erosion and that is to allow the closure of the Acela Acquisition

$CDIX’s last PR could not have made it any clearer their intentions to acquire Acela by their actions taken

Cardiff Lexington Corporation  (CDIX) Shores Up Balance Sheet with Capital Infusion; Eliminates Convertible Debts

2019-09-11, 8:45 AM

FT. LAUDERDALE, Fla., Sept. 11, 2019 (GLOBE NEWSWIRE) -- Cardiff Lexington (OTC: CDIX)  Cardiff Lexington, a public holding company, today announced that the Company has received $410,000.00 in new funding from the Private Equity Group, Leonite Capital, LLC. The parties entered into a 12-month conventional note. This capital infusion was arranged  by the registered Broker Dealer Craft Capital, LLC to stop the current convertible note dilution of Cardiff Lexington common stock and in an attempt to stabilize the share price of the Company.

Cardiff has paid-off three significant convertible notes totaling $379,902 and plans to retire all commercial notes by year end 2019 in concert with acquisition related equity funding. This move consolidates Company debt with essentially two friendly lenders Leonite Capital LLC and Greentree Financial, LLC both of whom have invested prior, are committed to future equity participations,  and are aligned and committed to Cardiff Lexington’s future goals and objectives.

Alex Cunningham, CEO/President of Cardiff Lexington, stated: “The elimination of troubling debt conversions from our balance sheet and move to an equity blend of financing should have a positive effect to help strengthen the value of our company and our common share market price. Paying off this currently converting convertible debt, will dramatically ease troubling dilution which has consistently put extreme pressure on our common stock price.  Our goal is to continue to reward our shareholders and new investors of Cardiff Lexington by organic growth through an increasing common stock price and expanding our revenue streams through new acquisitions including real estate and companies vertically and horizontally aligned with the CBD Oil Medical Hemp business. ”  “These moves combined with our  pending potential Acela BioMedical acquisition  in my opinion will immediately validate our higher standing within the small cap market segment as we continue to gain national attention of our business strategy as one of the more stable innovative fully reporting Companies in our industry,” further stated Cunningham.
About Cardiff Lexington Corporation: Cardiff Lexington is a public holding company, much like a cooperative, leveraging proven management in private companies that   become subsidiaries. Our focus is not industry or geographic-specific, but rather proven management, market, and margin. Cardiff Lexington targets acquisitions of mature, high growth, niche companies. Cardiff Lexington's strategy identifies and empowers select income-producing middle market private businesses and commercial real estate properties. Cardiff Lexington provides these companies both 1) the enhanced ability to raise money for operations or expansion, and 2) an equity exit and liquidity strategy for the owner, heirs, and/or Investors. For investors, Cardiff Lexington provides a diversified lower risk to protect and safely enhance their investment by  continually adding assets and holdings. Cardiff Lexington is led by strong and talented team of executives and advisors providing expert acquisition, market guidance and added value for subsidiaries and  investors.

FORWARD LOOKING STATEMENT: This news release contains forward looking statements within the meaning of the Securities Litigation Reform Act. The statements  reflect the Company's current views with respect to future events that involve risks and uncertainties. These risks include the failure to meet schedule or performance   requirements of the Company's contracts, the Company's liquidity position, the Company's ability to obtain new contracts, the emergence of competitors with greater financial resources, and the impact of competitive pricing. In the light of these uncertainties the forward-looking events referred to in this release might not occur.
Investors Relations 800-628- 2100  ext. 705
[e-mail]

MUST READ CDIX 7 DD Links!

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151276296

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151146856

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151276263

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150916701

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151166240

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150719782

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151217232

[shortburner]

TRANSPARENCY---openness, communication, accountability.
So if the last round of preferred shares converted 15 days ago the debt holder converts at 1/2 the price average for 15 days--so those .005's convert at .0025. and 50k at .0025 is 20 million shares---20 mil at .006 is what?----120k?
Are ya seeing a pattern here?
CDIX needs to clear the air here---in more ways than one...
If I had invested 50 k in the debt and could convert at 1/2 the lowest price I would damm sure be selling at .017...Because at that point in time the stock was trading at .0005---not .005
Are we seeing a pattern here yet????